Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027163 · ClinicalTrials.gov registry record
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 62
- Enrollment target
NCT07027163: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07027163 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07027163 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.
Primary Outcome
Patients were classified as treatment responders if an oral food challenge was negative, or a decrease in severity of food allergy during an oral food challenge was determined and no anaphylactic reactions occurred during treatment. Non-responders were those who experienced repetitive food anaphylactic reactions during treatment. Partial treatment responders were patients who experienced less than 1 food anaphylactic reaction despite undergoing treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-09-01 |
What the finished NCT07027163 record still lists
NCT07027163 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07027163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07027163 about?
NCT07027163 is a clinical study titled "A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis". This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combinat...
What is the current status of trial NCT07027163?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2023-06-01. Estimated completion is 2023-09-01.
Who is sponsoring clinical trial NCT07027163?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI